CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Nevirapine

奈韦拉平 杂质对照品Nevirapine Impurities

EP35 个杂质条目35 impurity entries

本页汇总 奈韦拉平 的 35 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 35 impurity reference standards of Nevirapine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 奈韦拉平(Nevirapine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating UHPLC method for determination of nevirapine in its bulk form and tablets: identification of impurities and degradation kinetic study
    Journal of pharmaceutical and biomedical analysis · 2016 · Reis NF et al.  ·  PMID 27179642  ·  DOI
  2. 杂质研究Impurity studiesValidation of a high-performance liquid chromatography method for the assay of and determination of related organic impurities in nevirapine drug substance
    Journal of chromatographic science · 2000 · Li QC et al.  ·  PMID 10890748  ·  DOI
  3. 杂质研究Impurity studiesIdentification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies
    Journal of pharmaceutical and biomedical analysis · 2009 · Qiu F et al.  ·  PMID 19201127  ·  DOI
  4. 分析方法Analytical MethodsRapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies
    Journal of chromatographic science · 2026 · Faria JC et al.  ·  PMID 42770255  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisInvestigating the continuous synthesis of a nicotinonitrile precursor to nevirapine
    Beilstein journal of organic chemistry · 2013 · Longstreet AR et al.  ·  PMID 24367421  ·  DOI

奈韦拉平 —— 原料药与杂质对照品Nevirapine — drug substance & impurities

共 36 个条目(含原料药本体)36 items incl. the drug substance
Nevirapine structure
EP原料药 APIAPI
奈韦拉平Nevirapine
Nevirapine
CAS No.129618-40-2
Chemical FormulaC15H14N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 1 (Nevirapine EP Impurity A) structure
EPA
奈韦拉平杂质1 (奈韦拉平EP杂质A)Nevirapine Impurity 1 (Nevirapine EP Impurity A)
Nevirapine Impurity 1 (Nevirapine EP Impurity A)
CAS No.133627-17-5
Chemical FormulaC14H14N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 2 (Nevirapine EP Impurity B) structure
EPB
奈韦拉平杂质2 (奈韦拉平EP杂质B)Nevirapine Impurity 2 (Nevirapine EP Impurity B)
Nevirapine Impurity 2 (Nevirapine EP Impurity B)
CAS No.287980-84-1
Chemical FormulaC12H10N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 3 (Nevirapine EP Impurity C) structure
EPC
奈韦拉平杂质3(奈韦拉平EP杂质C)Nevirapine Impurity 3 (Nevirapine EP Impurity C)
Nevirapine Impurity 3 (Nevirapine EP Impurity C)
CAS No.287980-85-2
Chemical FormulaC15H16N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 4 (Nevirapine EP Impurity D) structure
EPD
奈韦拉平杂质4 (奈韦拉平EP杂质D)Nevirapine Impurity 4 (Nevirapine EP Impurity D)
Nevirapine Impurity 4 (Nevirapine EP Impurity D)
CAS No.1391054-30-0
Chemical FormulaC30H26N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 5 structure
5
奈韦拉平杂质5Nevirapine Impurity 5
Nevirapine Impurity 5
CAS No.284686-16-4
Chemical FormulaC15H13N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 6 structure
6
奈韦拉平杂质6Nevirapine Impurity 6
Nevirapine Impurity 6
CAS No.284686-15-3
Chemical FormulaC15H15N5O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 7 structure
7
奈韦拉平杂质7Nevirapine Impurity 7
Nevirapine Impurity 7
CAS No.245500-91-8
Chemical FormulaC21H22N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 8 (2-Hydroxy Nevirapine) structure
8
奈韦拉平杂质8 (2-羟基奈韦拉平)Nevirapine Impurity 8 (2-Hydroxy Nevirapine)
Nevirapine Impurity 8 (2-Hydroxy Nevirapine)
CAS No.254889-31-1
Chemical FormulaC15H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 9 (3-Hydroxy Nevirapine) structure
9
奈韦拉平杂质9 (3-羟基奈韦拉平)Nevirapine Impurity 9 (3-Hydroxy Nevirapine)
Nevirapine Impurity 9 (3-Hydroxy Nevirapine)
CAS No.174532-82-2
Chemical FormulaC15H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 10 structure
10
奈韦拉平杂质10Nevirapine Impurity 10
Nevirapine Impurity 10
CAS No.284686-21-1
Chemical FormulaC15H13BrN4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 11 structure
11
奈韦拉平杂质11Nevirapine Impurity 11
Nevirapine Impurity 11
CAS No.284686-22-2
Chemical FormulaC17H16N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 12 structure
12
奈韦拉平杂质12Nevirapine Impurity 12
Nevirapine Impurity 12
CAS No.245500-93-0
Chemical FormulaC21H22N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 13 structure
13
奈韦拉平杂质13Nevirapine Impurity 13
Nevirapine Impurity 13
CAS No.245500-97-4
Chemical FormulaC21H22N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 14 structure
14
奈韦拉平杂质14Nevirapine Impurity 14
Nevirapine Impurity 14
CAS No.254889-32-2
Chemical FormulaC15H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 15 structure
15
奈韦拉平杂质15Nevirapine Impurity 15
Nevirapine Impurity 15
CAS No.133627-24-4
Chemical FormulaC15H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 16 structure
16
奈韦拉平杂质16Nevirapine Impurity 16
Nevirapine Impurity 16
CAS No.245500-95-2
Chemical FormulaC22H24N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 17 structure
17
奈韦拉平杂质17Nevirapine Impurity 17
Nevirapine Impurity 17
CAS No.284686-27-7
Chemical FormulaC18H18N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 18 structure
18
奈韦拉平杂质18Nevirapine Impurity 18
Nevirapine Impurity 18
CAS No.1046462-02-5
Chemical FormulaC16H16N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 19 structure
19
奈韦拉平杂质19Nevirapine Impurity 19
Nevirapine Impurity 19
CAS No.174532-77-5
Chemical FormulaC16H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 20 structure
20
奈韦拉平杂质20Nevirapine Impurity 20
Nevirapine Impurity 20
CAS No.135795-45-8
Chemical FormulaC14H15ClN4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 21 structure
21
奈韦拉平杂质21Nevirapine Impurity 21
Nevirapine Impurity 21
CAS No.284686-26-6
Chemical FormulaC18H18N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 22 structure
22
奈韦拉平杂质22Nevirapine Impurity 22
Nevirapine Impurity 22
CAS No.284686-24-4
Chemical FormulaC16H17ClN4OS
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 23 structure
23
奈韦拉平杂质23Nevirapine Impurity 23
Nevirapine Impurity 23
CAS No.156544-61-5
Chemical FormulaC7H14N2OS
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 24 structure
24
奈韦拉平杂质24Nevirapine Impurity 24
Nevirapine Impurity 24
CAS No.1796928-56-7
Chemical FormulaC15H13ClN4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 25 structure
25
奈韦拉平杂质25Nevirapine Impurity 25
Nevirapine Impurity 25
CAS No.245501-02-4
Chemical FormulaC15H12N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 26 structure
26
奈韦拉平杂质26Nevirapine Impurity 26
Nevirapine Impurity 26
CAS No.284686-19-7
Chemical FormulaC15H15ClN4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 27 structure
27
奈韦拉平杂质27Nevirapine Impurity 27
Nevirapine Impurity 27
CAS No.284686-17-5
Chemical FormulaC9H11N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 28 structure
28
奈韦拉平杂质28Nevirapine Impurity 28
Nevirapine Impurity 28
CAS No.1798004-92-8
Chemical FormulaC12H8Cl3N3O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 29 structure
29
奈韦拉平杂质29Nevirapine Impurity 29
Nevirapine Impurity 29
CAS No.132312-82-4
Chemical FormulaC15H16N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 30 structure
30
奈韦拉平杂质30Nevirapine Impurity 30
Nevirapine Impurity 30
CAS No.162255-73-4
Chemical FormulaC15H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 31 structure
31
奈韦拉平杂质31Nevirapine Impurity 31
Nevirapine Impurity 31
CAS No.133627-45-9
Chemical FormulaC6H7ClN2
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 32 structure
32
奈韦拉平杂质32Nevirapine Impurity 32
Nevirapine Impurity 32
CAS No.133627-46-0
Chemical FormulaC12H9Cl2N3O
Purity>95%询价On request
10mg25mg50mg100mg
Nevirapine Impurity 6-d3 structure
6-D3
奈韦拉平杂质6-d3Nevirapine Impurity 6-d3
Nevirapine Impurity 6-d3
CAS No.1346605-12-6
Chemical FormulaC15H12D3N5O
Purity>95%询价On request
Nevirapine Impurity 8-d3 (2-Hydroxy Nevirapine-d3) structure
8-D3
奈韦拉平杂质8-d3 (2-羟基奈韦拉平-d3)Nevirapine Impurity 8-d3 (2-Hydroxy Nevirapine-d3)
Nevirapine Impurity 8-d3 (2-Hydroxy Nevirapine-d3)
CAS No.1329834-05-0
Chemical FormulaC15H11D3N4O2
Purity>95%询价On request
Nevirapine Impurity 9-d3 (3-Hydroxy Nevirapine-d3) structure
9-D3
奈韦拉平杂质9-d3 (3-羟基奈韦拉平-d3)Nevirapine Impurity 9-d3 (3-Hydroxy Nevirapine-d3)
Nevirapine Impurity 9-d3 (3-Hydroxy Nevirapine-d3)
CAS No.1346602-85-4
Chemical FormulaC15H11D3N4O2
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

奈韦拉平 —— 研究文献与合成路线Nevirapine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 奈韦拉平 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Nevirapine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability-indicating UHPLC method for determination of nevirapine in its bulk form and tablets: identification of impurities and degradation kinetic study
    Reis NF, de Assis JC, Fialho SL, et al. · Journal of pharmaceutical and biomedical analysis · 2016 · 被引 4cited 4
  2. Identification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies
    Qiu F, Pennino S, Busacca CA, et al. · Journal of pharmaceutical and biomedical analysis · 2009 · 被引 5cited 5
  3. Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension
    Aparna P, Rao SV, Thomas KM, et al. · Die Pharmazie · 2010 · 被引 2cited 2
  4. Validation of a high-performance liquid chromatography method for the assay of and determination of related organic impurities in nevirapine drug substance
    Li QC, Tougas T, Cohen K, et al. · Journal of chromatographic science · 2000 · 被引 3cited 3
  5. Rapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies
    Faria JC, Todeschini V, da Silva Sangoi M · Journal of chromatographic science · 2026
  6. Solid-phase extraction combined with dispersive liquid-liquid microextraction/HPLC-UV as a sensitive and efficient method for extraction, pre-concentration and simultaneous determination of antiretroviral drugs nevirapine, efavirenz and nelfinavir in pharmaceutical formulations and biological samples
    Safari M, Shamsipur M, Zohrabi P, et al. · Journal of pharmaceutical and biomedical analysis · 2019 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. Process for preparing Nevirapine
    SANAPUREDDY JAGAN MOHAN REDDY, DANDALA RAMESH, MEENAKSHISUNDERAM SIVAKUMARAN · 公开号 US2010125137US2010125137 · 2010
  2. AN IMPROVED PROCESS FOR PREPARING NEVIRAPINE
    SANAPUREDDY JAGAN MOHAN REDDY, DANDALA RAMESH, MEENAKSHISUNDERAM SIVAKUMARAN · 公开号 EP2158196EP2158196 · 2010
  3. AN IMPROVED PROCESS FOR PREPARING NEVIRAPINE
    SANAPUREDDY JAGAN MOHAN REDDY, DANDALA RAMESH, MEENAKSHISUNDERAM SIVAKUMARAN · 公开号 WO2008142528WO2008142528 · 2008
  4. A POLYMORPH FORM OF NEVIRAPINE AND ITS PREPARATION
    STIEGER NICOLE, LIEBENBERG WILNA, CAIRA MINO RODOLFO · 公开号 WO2011073907WO2011073907 · 2011
  5. Novel method for preparing Nevirapine
    WEI ZHU, YONGAN HU, DAWEI MA, LIXIN GAN · 公开号 CN101585836CN101585836 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

奈韦拉平 杂质谱研究要点Nevirapine — impurity profiling notes

下面这些是拿到 奈韦拉平 的 36 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 36 impurity entries for Nevirapine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances